Last updated on September 2020

A Phase II Study in Patients With Moderate to Severe Active Ulcerative Colitis.

Brief description of study

The proposed study is a randomized, double-blind,placebo-controlled, multi-center phase II study to investigatethe safety and efficacy of SHR0302 in patients with moderate to severe activeulcerative colitis. The study aims to evaluate the optimal dose of SHR0302 andtime needed in inducing clinical response in active ulcerative colitispatients.

This is an 8+8 weeksstudy, in which participants who complete the first 8 weeks treatment phase, will have the option to enter a blinded activearms 8-week extension phase. Early withdrawn subjects during the first treatment phasecannot enter the extension phase. The total duration of the study participation, including extension and follow-up, will be approximately 18weeks.

SHR0302 is a JAK1 inhibitor, capable of blocking JAK-STATs pathway and control inflammation. Therefore it has the potential to be a treatment for UC.

Clinical Study Identifier: NCT03675477

Find a site near you

Start Over

NECCR Primacare Research, LLC

Fall River, MA United States
  Connect »

Digestive Disease Specialists, Inc.

Oklahoma City, OK United States
  Connect »

Univ. of Kansas Medical Center

Kansas City, MO United States
  Connect »

Wilmington Health

Wilmington, NC United States
  Connect »

The Jackson Clinic ,PA

Jackson, TN United States
  Connect »

PrimeCare Medical Group

Houston, TX United States
  Connect »

Nzoz Vivamed

Warszawa, Poland
  Connect »

Provita Profamilia

Piotrków Trybunalski, Poland
  Connect »

Nzoz Formed

Wadowice, Poland
  Connect »

IP Clinic

Łódź, Poland
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.